Expression/localization patterns of sirtuins (SIRT1, SIRT2, and SIRT7) during progression of cervical cancer and effects of sirtuin inhibitors on growth of cervical cancer cells

Tumor Biology

Volumn 36, Issue 8, 2015, Pages 6159-6171

  Singh, Sapna ^a,b   Kumar, P Uday ^b   Thakur, Suresh ^c   Kiran, Shashi ^a   Sen, Bijoya ^d   Sharma, Shreya ^d   Rao, Vishnu Vardhan ^b   Poongothai, A R ^c   Ramakrishna, Gayatri ^d  

^a CENTRE FOR DNA FINGERPRINTING AND DIAGNOSTICS   (India)

^b NATIONAL INSTITUTE OF NUTRITION   (India)

^c BioGenex Lab Inc   (India)

^d INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

Author keywords

AGK2 and EX527; Cancer progression; Cervical cancer; Sirtuins

Indexed keywords

AGK 2; HYDROLASE INHIBITOR; KI 67 ANTIGEN; PROTEIN P27; SELISISTAT; SIRTINOL; SIRTUIN 1; SIRTUIN 2; SIRTUIN 7; UNCLASSIFIED DRUG; 6-CHLORO-2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-1-CARBOXAMIDE; AGK2 COMPOUND; CARBAZOLE DERIVATIVE; FURAN DERIVATIVE; QUINOLINE DERIVATIVE; SIRT1 PROTEIN, HUMAN; SIRT2 PROTEIN, HUMAN; SIRT7 PROTEIN, HUMAN; SIRTUIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CELL CYCLE ARREST; CELL DEATH; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOSTASIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SPECIFICITY; ELECTROPHORETIC MOBILITY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOGENESIS; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HELA CELL LINE; PATHOLOGY; UTERINE CERVICAL NEOPLASMS;

CARBAZOLES; CARCINOGENESIS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; FEMALE; FURANS; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; QUINOLINES; SIRTUIN 1; SIRTUIN 2; SIRTUINS; UTERINE CERVICAL NEOPLASMS;

EID: 84940440362     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3300-y     Document Type: Article

References (44)

1. Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance annual review of pathology: mechanisms of disease. Annu Rev Pathol Mech Dis. 2010;5:253–95.
2. Nogueiras R, Habegger KM, Chaudhary N, Finan B, Banks AS, Dietrich MO, et al. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev. 2012;92:1479–14.
3. Polito L, Kehoe PG, Forloni G, Albani D. The molecular genetics of sirtuins: association with human longevity and age-related diseases. Int J Mol Epidemiol Genet. 2010;1:214–25.
4. Presegue LB, Vaquero A. Dual role of sirtuins in cancer. Gene Cancer. 2011;2:648–62.
5. Deng CX. SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci. 2009;5:147–52.
6. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, et al. hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001;107:149–59.
7. Li S, Banck M, Mujtaba S, Zhou MM, Sugrue MM, Walsh MJ. p53-induced growth arrest is regulated by the mitochondrial SirT3 deacetylase. PLoS One. 2010;5:e10486.
8. Wang R, Sengupta K, Li C, Kim H, Cao L, Xiao C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell. 2008;14:312–23.
9. Kim HS, Patel K, Jacobs KM, Bisht KS, Aykin-Burns N, Pennington JD, et al. SIRT3 is a mitochondrial-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell. 2010;17:41–52.
10. North BJ, Verdin E. Mitotic regulation of SIRT2 by cyclin-dependent kinase 1-dependent phosphorylation. J Biol Chem. 2007;282:19546–55.
11. Jeong SM, Xiao C, Finley LWS, Lahusen T, Souza AL, Pierce K, et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell. 2013;23:450–63.
12. Van Meter M, Mao Z, Gorbunova V, Seluanov A. Repairing split ends: SIRT6, mono-ADP ribosylation and DNA repair. Aging. 2011;3:829–35.
13. Barber MF, Michishita-Kioi E, Xi Y, Tasselli L, Kioi M, Mogtaderi Z, et al. SIRT7 link H3K18 deacetylation to maintenance of oncogenic transformation. Nature. 2012;487:114–8.
14. Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH, Park HS, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Ciln Cancer Res. 2009;15:4453–9.
15. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res. 1998;58:5489–94.
16. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007;67:6612–8.
17. Chen J, Zhang B, Wong N, Lo AWI, To KF, Chang AWH, et al. Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res. 2011;71:4138–49.
18. Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ, Kim MG, et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology. 2013;57:1055–67.
19. Kim HS, Vassilopoulous A, Wang RH, Lahusen T, Xiao T, Xu X, et al. SIRT2 maintain genomic integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell. 2011;20:487–99.
20. McGlynn LM, Zino S, MacDonald AI, Curle J, Reilly JE, Mohammed ZM, et al. SIRT2: tumor suppressor or tumor promoter in operable breast cancer. Eur J Cancer. 2014;50:290–301.
21. Finley LW, Carracedo A, Lee J, Souza A, Egia A, Zhang J, et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell. 2011;19:416–28.
22. Alhazzazi TY, Kamarajan P, Joo N, Huang JY, Verdin E, D’Silva NJ, et al. Sirtuin-3(SIRT3), a novel potential therapeutic target for oral cancer. Cancer. 2011;117:1670–8.
23. Marquardt JU, Fischer K, Teufel A, Krupp M, Thorgeirsson SS, Galle PR, et al. Loss of SIRT6 in hepatocellular carcinoma: associated molecular traits and clinical implications. Z Gastroenterol. 2012;50:5–34.
24. Benavente CA, Schnell SA, Jacobson EL. Effects of niacin restriction on sirtuin and PARP responses to photodamage in human skin. PLoS One. 2012;7:e42276.
25. Lai CC, Lin PM, Lin SF, Hsu CH, Lin HC, Hu ML, et al. Altered expression of SIRT gene family in head and neck squamous cell carcinoma. Tumor Biol. 2013;34:1847–54.
26. Allison SJ, Jiang M, Milner J. Oncogenic viral protein HPV E7 up-regulates the SIRT1 longevity protein in human cervical cancer cells. Aging. 2009;1:316–27.
27. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell. 2005;16:4623–35.
28. Kiran S, Anwar T, Kiran M, Ramakrishna G. Sirtuin 7 in cell proliferation, stress and disease: rise of the seventh Sirtuin! Cell Signal. 2015;3:673–82.
29. Villalba JM, Alcaín FJ. Sirtuin activators and inhibitors. Biofactors. 2012;38:349–59.
30. Feng W, Xiao J, Zhang Z, Rosen DG, Brown RE, Liu J, et al. Senescence and apoptosis in carcinogenesis of cervical squamous carcinoma. Mod Pathol. 2007;20:961–6.
31. Lomnytska MI, Becker S, Bodin I, Olsson A, Hellman K, Hellstrȍm A-C, et al. Differential expression of ANXA6, HSP27, PRDX2, NCF2, and TPM4 during uterine cervix carcinogenesis: diagnostic and prognostic value. Br J Can. 2011;104:110–9.
32. Ram BM, Ramakrishna G. Endoplasmic reticulum vacuolation and unfolded protein response leading to paraptosis like cell death in cyclosporine A treated cancer cervix cells is mediated by cyclophilin B inhibition. Biochim Biophys Acta. 2014;1843(11):2497–512.
33. Kiran S, Chatterjee N, Singh S, Kaul SC, Wadhwa R, Ramakrishna G. Intracellular distribution of human SIRT7 and mapping of the nuclear/nucleolar localization signal. FEBS J. 2013;280:3451–66.
34. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001;25:402–8.
35. Maxwell MM, Tomkinson EM, Nobles J, Wizeman JW, Amore AM, Quinti L, et al. The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS. Hum Mol Genet. 2011;15:3986–96.
36. Chhabra S, Bhavani M, Mahajan N, Bawaskar R. Cervical cancer in Indian rural women: trends over two decades. J Obstet Gynaecol. 2010;30:725–8.
37. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24(S3):1–10.
38. Ota H, Tokunaga E, Chang K, Hikasa M, Iijima K, Eto M, et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene. 2006;25:176–85.
39. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, et al. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem. 2009;284:18210–7.
40. Byles V, Chmilewski LK, Wang J, Zhu L, Forman LW, Faller DV, et al. Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signalling in human cancer cells. Int J Biol Sci. 2010;6:599–612.
41. Kuo SJ, Lin HY, Chien SY, Chen DR. SIRT1 suppresses breast cancer growth cancer growth through downregulation of Bcl-2 protein. Oncol Rep. 2013;30:125–30.
42. Jang KY, Hwang SH, Kwon KS, Kang MJ, Lee DG, Kim HS, et al. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol. 2008;32:1523–31.
43. Hou H, Chen W, Zhao L, Zuo Q, Zhang G, Zhang X, et al. Cortactin is associated with tumor progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ. J Clin Pathol. 2012;65:1088–96.
44. Chen J, Chan AW, To KF, Chen W, Zhang Z, Ren J, et al. SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3β/β-catenin signaling. Hepatology. 2013;57:2287–98.